DNA sequencing produces a mass amount of data. As the technology has improved, magnitudes more data gets produced per sequence. Translating this progress into a clinical setting requires storage, sharing, and analyses of immense information sets. But is big data the largest hurdle facing mainstream application of genomics?
There is a lot of talk in the life science industry about the “big data” problem, specifically related to the large sets of data produced by modern sequencing. Creating a system to efficiently store, analyze, and share the terabytes of information produced by sequencing a large amount of patients is certainly important for the adoption of genomics into regular patient care, but is an absolutely workable problem. New Amsterdam Genomics has faced this issue head-on, and is uniquely equipped to continue to innovate as the amount of patients who undergo genetic testing rapidly increases.
Next Generation Sequencing undoubtedly presents computing challenges, but this is hardly an issue unique to genomics. The financial, agriculture and advertising industries have viable solutions for many of these issues that can be translated for application in clinical care. Even healthcare has approached the topic before, with big data lending a hand in higher quality patient tracking for large programs, like Medicaid. Other fields of science have confronted these problems as well, particularly in physics, where CERN produces over 30 petabytes of data annually, shared across the global scientific community.
The true challenge of getting genomics into everyday practice is access. New Amsterdam Genomics understands this well, and has developed the infrastructure to do exactly that. Much of the currently available genomic technology exists solely in research institutions or private labs. By connecting the capabilities of testing labs with private practices, in a physician friendly workflow, the size and location of a practice no longer matters when it comes to the ability to provide in-depth genomic testing. New Amsterdam Genomics has achieved this by partnering with sequencing labs, and providing our own powerful analysis, via a proprietary machine learning algorithm, in order to reveal the most important information raw genomic data has to offer a clinical physician.
The last big hurdle in providing the highest quality genomic medicine to hundreds of thousands of patients isn’t outdated technology or cost, it’s access and proper analyses. New Amsterdam Genomics has bridged this gap with industry-leading solutions, bringing the future of genomic medicine to practices across the country.